Palvella Soars After Positive Phase 3 Data – First Approved Therapy for Microcystic LMs in Sight

Palvella Therapeutics shares surged 30% after strong Phase 3 SELVA trial data for QTORIN rapamycin gel in microcystic lymphatic malformations. First potential FDA-approved treatment could arrive in 2027.